Serum α1-acid glycoprotein concentrations before and after relapse in dogs with lymphoma treated with doxorubicin

Journal of the American Veterinary Medical Association

Volumn 214, Issue 7, 1999, Pages 1023-1025

  Hahn, Kevin A ^a   Freeman, Kimberly P ^a   Barnhill, Mary A ^a   Stephen, Edward L ^b  

^a UNIVERSITY OF TENNESSEE   (United States)

^b Devmt Technol International Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; OROSOMUCOID;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; DRUG RESPONSE; FEMALE; LYMPH NODE; LYMPHOMA; MALE; NONHUMAN; RECURRENCE RISK; RECURRENT DISEASE; RELAPSE; REMISSION;

ANIMALS; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DOG DISEASES; DOGS; DOXORUBICIN; FEMALE; LYMPHOMA; MALE; OROSOMUCOID; RECURRENCE; REMISSION INDUCTION;

EID: 0033119237     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Freedman AS, Nadler LM. Non-Hodgkin's lymphomas. In: Holland JF, Bast RC, Morton DL, et al, eds Cancer medicine. 4th ed Philadelphia: The Williams & Wilkins Co, 1997;2757-2796.
2. Hahn KA, Richardson RC, Cline MA, et al. Is maintenance chemotherapy appropriate for the management of canine malignant lymphoma? J Vet Intern Med 1992;6:3-10.
3. Lee JJ, Hughes CS, Fine RL, et al. P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance. Cancer 1996;77:1982-1988.
4. Ginn PE. Immunohistochemical detection of P-glycoprotein in formalin-fixed and paraffin-embedded normal and neoplastic canine tissues. Vet Pathol 1996;33:533-541.
5. Child JA, Cooper EH, Illingworth S, et al. Biochemical markers in Hodgkin's disease and non-Hodgkin's lymphoma. Recent Results Cancer Res 1978;64:180-189.
6. Xie JE Clinical significance of serum ferritin and acute phase reactant protein levels in patients with cervical cancer. Chung Hua Fu Chan Ko Tsa Chi 1991;26:92-94.
7. Saito T, Kuwahara A, Shimoda K, et al. Factors influencing the acute phase protein levels in patients with esophageal cancer. Jpn J Surg 1991;21:402-411.
8. Avail Lundquist E, Blad E, Xiao L, et al. Pretreatment serum levels of C-reactive protein, alpha 1-antitrypsin, haptoglobin, alpha 1-acid glycoprotein and tissue polypeptide antigen in cervical carcinoma. Eur J Gynicol Oncol 1991;12:375-383.
9. Stamatiadis AP, St. Toumanidou M, Vyssoulis GP, et al. Value of serum acute-phase reactant proteins and carcinoembryonic antigen in the preoperative staging of colorectal cancer. Cancer 1990;65:2055-2057.
10. 1-acid glycoprotein to monitor therapy of cancer patterns. J Natl Cancer Inst 1983;71:25-30.
11. 1-acid glycoprotein in dogs with malignant neoplasia. J Am Vet Med Assoc 1993;203:1144-1146.
12. Henderson RA, Brawner WR, Brewer WG, et al. Clinical staging. In: Hahn KA, Richardson RC, eds Cancer chemotherapy, a veterinary handbook. Philadelphia: The Williams & Wilkins Co, 1995;23-46.
13. Steel RGD, Torrie JH. Principles and procedures of statistics. New York: McGraw-Hill Book Co, 1980;8-38.
14. 1-acid glycoprotein in cattle with neoplastic and inflammatory diseases. J Jpn Vet Med Assoc 1990;43:19-23.
15. Weiner M. Serum protein changes during the acute phase reaction. Clin Chim Acta 1969;25:299-305.
16. Gottesman MM. How cancer cells evade chemotherapy. Cancer Res 1993;53:747-754.
17. Cummings, J, Willmott N, Hoey BM, et al. The consequences of doxorubicin quinone reduction in vivo in tumor tissue. Biochem Pharmacol 1992;44:2165-2174.